Table 5.
Distribution of Saudi MS patients according to BI (N=207).
| Variables | BI | P-value | ||
|---|---|---|---|---|
| Independent | Dependent | Total | ||
| n (%) | ||||
| Gender | ||||
| Male | 55 (29.9) | 9 (40.9) | 64 (30.9) | 0.366 |
| Female | 130 (70.3) | 13 (59.1) | 143 (69.1) | |
| Smoking | ||||
| Yes | 36 (19.5) | 2 (9.1) | 38 (18.4) | 0.385 |
| No | 143 (77.3) | 19 (86.4) | 162 (78.3) | |
| Quit | 6 (3.2) | 1 (4.5) | 7 (3.4) | |
| Attacks last year | ||||
| Yes | 67 (36.2) | 12 (54.5) | 79 (38.2) | 0.054 |
| No | 118 (63.8) | 10 (45.5) | 128 (61.8) | |
| Delayed diagnosis | ||||
| Yes | 51 (27.6) | 7 (31.8) | 58 (28) | 0.444 |
| No | 134 (72.4) | 15 (68.2) | 149 (72) | |
| Medication use | ||||
| Yes | 142 (76.8) | 17 (77.3) | 159 (76.8) | 1.000 |
| No | 43 (23.2) | 5 (22.7) | 48 (23.2) | |
| Compliance | ||||
| Compliant | 114 (80.3) | 13 (76.5) | 127 (79.9) | 0.044 |
| Moderate | 16 (11.3) | 0 (0) | 16 (10.1) | |
| Not compliant | 12 (8.5) | 4 (23.5) | 16 (10.1) | |
| Current medication | ||||
| Interferon beta-1a (Avonex) | 13 (9.2) | 0 (0) | 13 (8.2) | 0.324 |
| Glatiramer acetate | 1 (0.7) | 0 (0) | 1 (0.6) | |
| Interferon beta-1a (Rebif) | 55 (38.7) | 8 (47.1) | 63 (39.6) | |
| Teriflunomide | 9 (6.3) | 3 (17.6) | 12 (7.5) | |
| Fingolimod | 43 (30.3) | 2 (11.8) | 45 (28.3) | |
| Dimethyl fumarate | 3 (2.1) | 2 (11.8) | 5 (3.1) | |
| Alemtuzumab | 3 (2.1) | 0 (0) | 3 (1.9) | |
| Natalizumab | 14 (9.9) | 2 (11.8) | 16 (10.1) | |
| Daclizumab | 1 (0.7) | 0 (0) | 1 (0.6) | |
MS - multiple sclerosis, BI - Barthel index